Navigation Links
Watson Third Quarter 2011 Net Revenue Climbs 23% to $1.1 Billion; Non-GAAP Diluted EPS of $1.09; GAAP Diluted EPS of $0.54
Date:11/1/2011

PARSIPPANY, N.J., Nov. 1, 2011 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today reported net revenue of $1.1 billion for the third quarter ended September 30, 2011, an increase of 23 percent when compared to $882.4 million in the third quarter 2010. On a non-GAAP basis, net income for the third quarter 2011 increased 31 percent to $138.7 million or $1.09 per diluted share, compared to $105.9 million or $0.85 per diluted share in the third quarter 2010.  GAAP diluted earnings per share for the third quarter 2011 were $0.54, compared to $0.21 in the prior year period. Refer to the attached reconciliation tables for adjustments to GAAP earnings.

For the third quarter 2011, adjusted EBITDA increased 22 percent to $258.2 million, compared to $211.1 million for the third quarter 2010.   Cash and marketable securities were $172.5 million as of September 30, 2011.

"Our exceptional performance in the third quarter, as measured by double-digit revenue and earnings growth, was driven once again by our focus on the execution of our business growth strategies in Global Generics and Brands and our continued focus on operational excellence," said Paul Bisaro, President and CEO. "Revenue growth of nearly 40 percent in our Global Generics segment came from sales of our extended release and oral contraceptive franchises in the US, and increased international product sales including the addition of Specifar. Growth in our Global Brands segment came from continued strong sales of our key promoted products including RAPAFLO®, which reached a milestone of more than 500,000 prescriptions dispensed since launch."

"With revenues exceeding $1 billion for the second consecutive quarter, we are utilizing our earnings and cash flow to continue our strategic investment into future growth drivers, while strengthening our balance sheet to drive further expans
'/>"/>

SOURCE Watson Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related medicine technology :

1. Watson Confirms Court Grants Preliminary Injunction Preventing Launch of Generic LOVENOX®
2. Watson to Present at the 2011 Annual Credit Suisse Health Care Conference
3. Watson Confirms Daytrana(R) Patent Challenge
4. Watson Provides Update on District Court Order Concerning Generic Version of LOVENOX®
5. Watson Confirms District Court Order Concerning Generic Version of LOVENOX(R)
6. Watson Confirms EMBEDA(R) Patent Challenge
7. Watson Launches Generic FEMCON(R) Fe
8. Watson to Host Conference Call and Webcast to Discuss Third Quarter 2011 Earnings
9. Watson to Present at the Jefferies 2011 Global Healthcare Conference
10. Watson Confirms Amphastar Patent Lawsuit
11. Watson Pharmaceuticals Announces Approval of Amphastars Generic LOVENOX(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... WOONSOCKET, R.I. , Jan. 15, 2014 MultiCell ... has filed a U.S. provisional patent application concerning composition ... formulations to achieve targeted tumor cell death.  ... very small noncoding double stranded RNA molecules (VSRNAs) which ...
(Date:1/15/2014)... YORK , Jan. 15, 2014 ... report is available in its catalogue: ... India Drug Forecast and Market Analysis to ... PharmaPoint: Atopic Dermatitis - India Drug ...
(Date:1/15/2014)... 15, 2014  A novel wearable injector slightly larger than an ... patients to self-inject prescription drugs in the large doses required ... diseases, autoimmune deficiencies, and genetic disorders.  An ... by 2018, according to analysts.   Many of these drugs will ...
Breaking Medicine Technology:MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2
... New data show the,investigational drug tetrabenazine maintained ... up to 80 weeks in those,patients who ... data suggest that tetrabenazine can be used ... use., "These findings demonstrate the potential benefit ...
... Pharmaceuticals plc,(LSE: CEN), the Cambridge based biopharmaceutical company, ... respected scientific,journal 'Synapse'* on its Phase II NMDA ... a potential treatment for neuropathic,pain. The independent study ... with CNS 5161. , In the study reported ...
Cached Medicine Technology:Clinical Trial Results Suggest Long-Term Treatment Benefit of,Tetrabenazine for Chorea Associated with Huntington's Disease 2Clinical Trial Results Suggest Long-Term Treatment Benefit of,Tetrabenazine for Chorea Associated with Huntington's Disease 3Independent publication supports the profile of CeNeS phase II,compound, CNS 5161 2Independent publication supports the profile of CeNeS phase II,compound, CNS 5161 3
(Date:4/22/2014)... percent of all lung cancers are small cell ... develop resistance to chemotherapy. However, researchers at Virginia ... insights into the mechanisms leading to this resistance ... Chemotherapies work primarily by mediating B-cell lymphoma 2 ... cell death. Depending on their function, this family ...
(Date:4/22/2014)... have found a way to block abnormal cholesterol production, ... the main cause of heart attacks and strokes and ... develops when fat builds inside blood vessels over time ... their ability to feed oxygen-rich blood to the heart ... experiments, described April 7 in the journal Circulation ...
(Date:4/22/2014)... massive health care spending, a new RAND study concludes ... incentivize pharmaceutical companies and device makers to develop products ... medical technologies and their use, a new study suggests ... medical devices get created in the first place. The ... as little loss of health as possible and to ...
(Date:4/22/2014)... nanodot technology, Berkeley Lab researchers have demonstrated the ... used to study the membranes of living cells. ... structures can reveal information critical to whether a ... cancerous, that can,t be obtained through conventional microscopy. ... provide a physical means to both probe and ...
(Date:4/22/2014)... (trade name: NovoEight) has been approved since November 2013 ... with haemophilia A. In an early benefit assessment pursuant ... for Medicinal Products" (AMNOG), the German Institute for Quality ... new active ingredient offers an added benefit over the ... an added benefit of turoctocog alfa is not proven. ...
Breaking Medicine News(10 mins):Health News:Scientists pinpoint protein that could improve small cell lung cancer therapies 2Health News:Scientists alter fat metabolism in animals to prevent most common type of heart disease 2Health News:Scientists alter fat metabolism in animals to prevent most common type of heart disease 3Health News:Scientists alter fat metabolism in animals to prevent most common type of heart disease 4Health News:US medical innovation needs smarter incentives to cut health spending, study finds 2Health News:US medical innovation needs smarter incentives to cut health spending, study finds 3Health News:First size-based chromatography technique for the study of livi 2Health News:First size-based chromatography technique for the study of livi 3Health News:Turoctocog alfa in patients with hemophilia A: Added benefit not proven 2Health News:Turoctocog alfa in patients with hemophilia A: Added benefit not proven 3
... and SANTA CLARA, Calif., Jan. 13 Gulf ... care facilities in,the nation, announced it will be ... ultrasound platforms from Eklin Medical Systems.,GCVS currently uses ... and Communications System) as part of the,facility,s Eklin ...
... respiratory distress, researchers say; company says product is safe ... cold remedy Vicks VapoRub may cause airway inflammation that ... study says. , Doctors at Wake Forest University started ... developed severe respiratory distress after the salve had been ...
... Interventions Incorporated into, First-of-its-Kind Study ... Jan. 13 /PRNewswire/ - MEMOTEXT announced today that ... will conduct a clinical trial on patient adherence ... technology developed by MEMOTEXT. The clinical trial, titled ...
... KENNEBUNK, Maine, Jan. 13 The new year brings ... its steadfast commitment to community programs. This month, the ... brings everyday Americans and local communities together with Tom,s ... care for families in need. Over the past four ...
... new turn. Now you can see the ... Early on Christmas morning, CNN ... "What is Telemedicine?" demonstrating how telemedicine is ... healthcare to patients at six area Walmart ...
... Synergy Connect(TM) links health plan, physicians and ... Fla., Jan. 13 Health Integrated, a ... helping people with chronic illnesses get the ... communities. Health Integrated,s groundbreaking Synergy Connect(TM) service ...
Cached Medicine News:Health News:Gulf Coast Veterinary Specialists to Expand Comprehensive Eklin Digital Practice(R) Solutions 2Health News:Gulf Coast Veterinary Specialists to Expand Comprehensive Eklin Digital Practice(R) Solutions 3Health News:Vicks VapoRub Linked to Infant Breathing Problems 2Health News:Vicks VapoRub Linked to Infant Breathing Problems 3Health News:MEMOTEXT Collaborating with Johns Hopkins University To Evaluate Technology-Driven Adherence Programs 2Health News:MEMOTEXT Collaborating with Johns Hopkins University To Evaluate Technology-Driven Adherence Programs 3Health News:MEMOTEXT Collaborating with Johns Hopkins University To Evaluate Technology-Driven Adherence Programs 4Health News:Tom's of Maine Invites Everyone to Start the New Year by Helping Families in Need 2Health News:Houston's NuPhysicia LLC has Remote Medical Technologies and Services Featured on CNN Health Report 2Health News:Houston's NuPhysicia LLC has Remote Medical Technologies and Services Featured on CNN Health Report 3Health News:Health Integrated Unifies Care Community to Improve Physical, Psychological and Social Health of the Chronically Ill 2Health News:Health Integrated Unifies Care Community to Improve Physical, Psychological and Social Health of the Chronically Ill 3
Inquire...
Rapid Urease test for the presumptive identification of H. pylori in gastric mucosal biopsies...
... The QuickVue H.pylori gII test is a ... qualitative detection of IgG antibodies specific to ... whole blood. It utilizes a convenient, non-invasive, ... aid physicians in the diagnosis of H.pylori ...
... a visually read, qualitative immunochromatographic method for ... a bacterium that grows in the stomach ... and some gastric cancers. FlexSure HP, available ... serum samples, provides the physician with the ...
Medicine Products: